The lack of clinical responses in our AML and solid tumour dose-escalation studies suggests that targeting the PIM pathway with monotherapy may be insufficient to impact refractory AML or advanced solid malignancies. This evidence concerns the gene PIM1 and acute myeloid leukemia.